GSA Capital Partners LLP cut its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 71.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 27,999 shares of the biopharmaceutical company’s stock after selling 69,700 shares during the period. GSA Capital Partners LLP owned about 0.07% of Emergent Biosolutions worth $949,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Riverhead Capital Management LLC raised its position in shares of Emergent Biosolutions by 102.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after purchasing an additional 1,542 shares during the period. Creative Planning lifted its stake in shares of Emergent Biosolutions by 1.2% during the 2nd quarter. Creative Planning now owns 4,555 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 55 shares in the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Emergent Biosolutions by 17.3% during the 1st quarter. Envestnet Asset Management Inc. now owns 5,710 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 844 shares in the last quarter. Laurion Capital Management LP purchased a new position in shares of Emergent Biosolutions during the 2nd quarter valued at $214,000. Finally, State of Alaska Department of Revenue lifted its stake in shares of Emergent Biosolutions by 79.9% during the 2nd quarter. State of Alaska Department of Revenue now owns 6,871 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 3,051 shares in the last quarter. 85.35% of the stock is owned by hedge funds and other institutional investors.

Shares of Emergent Biosolutions, Inc. (EBS) opened at 40.45 on Monday. Emergent Biosolutions, Inc. has a 52 week low of $24.47 and a 52 week high of $40.60. The company’s 50-day moving average price is $36.27 and its 200 day moving average price is $32.70. The company has a market cap of $1.67 billion, a P/E ratio of 25.76 and a beta of 1.26.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 EPS for the quarter, missing the Zacks’ consensus estimate of $0.26 by ($0.13). Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The business had revenue of $100.77 million for the quarter, compared to analyst estimates of $111.57 million. During the same quarter last year, the business earned ($0.05) earnings per share. Emergent Biosolutions’s revenue was up 10.4% on a year-over-year basis. Equities research analysts anticipate that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the stock. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research note on Friday, August 25th. Finally, Zacks Investment Research cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a report on Friday, August 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. Emergent Biosolutions currently has a consensus rating of “Buy” and an average target price of $45.00.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Watch List News and is the property of of Watch List News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/gsa-capital-partners-llp-has-949000-stake-in-emergent-biosolutions-inc-ebs/1602805.html.

In other Emergent Biosolutions news, Chairman Fuad El-Hibri sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $40.50, for a total value of $1,012,500.00. Following the sale, the chairman now directly owns 1,555,216 shares of the company’s stock, valued at $62,986,248. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $37.06, for a total value of $292,218.10. Following the completion of the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,257,482.86. The disclosure for this sale can be found here. Insiders sold a total of 230,227 shares of company stock valued at $8,793,970 in the last ninety days. 16.50% of the stock is currently owned by insiders.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions, Inc. (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.